Drug Trial Radar · NCT07804368
Platform Trial for Salvage Consolidation Therapy in Dimorphic Fungi
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Dec 1, 2028
Study completion Dec 1, 2028
Sponsor
- Lead sponsor
- University of MinnesotaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Centers for Disease Control and Prevention; University of Alabama at Birmingham
- First posted
- Sep 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase II platform trial will evaluate the safety, tolerability, and effectiveness of investigational antifungal agents as salvage or consolidation therapy in adults with dimorphic fungal infections, including coccidioidomycosis, blastomycosis, and histoplasmosis. The study will enroll adults who are receiving active antifungal therapy and who have intolerance, failure, or unavailability of standard first-line consolidation therapy. The first investigational agent evaluated in the platform trial is oteseconazole. Participants will receive study drug and complete follow-up assessments for symptom status, functional status, adverse events, laboratory safety, study drug discontinuation, and quality of life. Participants will be followed during therapy and for up to 6 months after therapy.
Conditions
- Coccidioidomycosis
- Blastomycosis
- Histoplasmosis
- Dimorphic Fungal Infection
- Endemic Mycoses
Interventions
OteseconazoleDrug
Participants will receive oral oteseconazole 600 mg twice daily for 12 days, followed by 600 mg weekly. Total treatment duration depends on diagnosis: up to 52 weeks for coccidioidomycosis, 26 weeks for blastomycosis, and 26 weeks for histoplasmosis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Symptom StatusTime frame: Baseline through 12 months
- Change in Functional StatusTime frame: Baseline through 12 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona
Arizona State University - Tempe Campus
Tempe, Arizona
University of California, Davis
Davis, California
UCSF Fresno
Fresno, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.